Resources

Technical notes, application notes and protocols that feature Combinati technology across various research areas, key applications, and assay scale. 

  • All
  • Infectious Disease
  • Oncology
  • Reproductive Health
All
  • All
  • Infectious Disease
  • Oncology
  • Reproductive Health
Oncology

Experiment Flexibility with the Combinati™ Absolute Q Digital PCR Platform

Microfluidic Array Partitioning (MAP) technology utilizes fixed microchamber arrays and positive pneumatic pressure to partition reagents and perform digital PCR, instead of using fluid-shearing to generate droplets.

LEARN MORE
Infectious Disease

SARS-CoV-2 Reference Material Quantification on the Absolute Q dPCR Platform

To address the need for a reliable method of accurate and precise measurements of SARS-CoV-2 samples, we leverage the Combinati Absolute Q Digital PCR (dPCR) platform, to quantify commercially available SARS-CoV-2 reference control material.

LEARN MORE
Oncology

IDT rhAmp EGFR p.T790M Genotyping on the Combinati Absolute Q

Integrated DNA Technologies’ rhAmp SNP Genotyping System enables highly precise interrogation of SNPs within difficult genomic regions. For the first time, the IDT rhAmp assay performance was demonstrated on a digital PCR platform — quantifying EGFR p.T790M mutation down to 0.1%.

LEARN MORE
Oncology

BCR/ABL Gene Expression Assay on the Combinati Absolute Q

95% of Chronic Myeloid Leukemia (CML) cases are characterized by the presence of a BCR-ABL1 fusion gene. Regular monitoring involving precise quantification of BCR-ABL1 transcripts is integral to successful tyrosine kinase inhibitor (TKI) treatment. Read more about how samples with precise ratios of BCR-ABL1/ABL1 were created and confirmed on the Combinati dPCR platform.

LEARN MORE
Reproductive Health

Quadruplex Absolute Q Digital PCR for Spinal Muscular Atrophy (SMA) Screening

Spinal muscular atrophy (SMA), a genetic neuromuscular disorder and leading genetic cause of infant mortality. Here we describe a 4-color multiplexing digital PCR solution on the Combinati Absolute Q to meet the growing demand for rapid SMA newborn screening and treatment.

LEARN MORE
Oncology

TaqMan™ Liquid Biopsy assays for rare target quantification

Digital PCR (dPCR) enables rare target detection even in the presence of high non-target background. Read more about how the Applied Biosystems™ TaqMan™ Liquid Biopsy dPCR Assays were used to perform rare target detection for 5 hot-spot cancer mutations on the Combinati Absolute Q platform.

LEARN MORE